In 2024, the business plans to partner with Novartis’ Sandoz to co-produce and market Humira biosimilar Hyrimoz (adalimumab-adaz) for more than 80 percent less than the biologic’s price, which is nearly $7,000 a month.
“The Cordavis products will be FDA approved, high quality and easy for patients to use and will help ensure consistent long-term supply of affordable biosimilars,” CVS said in a statement.
The Cordavis launch coincides with a workforce restructuring of about 2 percent of its total workforce. CVS is cutting 5,000 jobs and has filed WARN notices for laying off 2,705 workers across nine states.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
